Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs

By Watson D.J.   Bolognese J.A.   Yu C.   Krupa D.   Curtis S.  

Current Medical Research and Opinion, Vol. 20, Iss. 12, 2004-12 ,pp. : 1899-1908

Informa Healthcare

Access to resources Recommend Favorite

The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis

By Ramey Dena R.   Watson Douglas J.   Yu Chang   Bolognese James A.   Curtis Sean P.   Reicin Alise S.  

Current Medical Research and Opinion, Vol. 21, Iss. 5, 2005-05 ,pp. : 715-722

Informa Healthcare

Access to resources Recommend Favorite

Safety of Etoricoxib, Celecoxib, and Nonselective Nonsteroidal Antiinflammatory Drugs in Ankylosing Spondylitis and Other Spondyloarthritis Patients: A Swedish National Population‐Based Cohort Study

By  

ARTHRITIS CARE AND RESEARCH, Vol. 67, Iss. 8, 2015-08 ,pp. : 1137-1149

John Wiley & Sons Inc

Access to resources Recommend Favorite

Issues in the Treatment of Ankylosing Spondylitis with Non-Steroidal Anti-Inflammatory Drugs

By van der Linden Sjef  

Wiener Medizinische Wochenschrift, Vol. 158, Iss. 7-8, 2008-05 ,pp. : 195-199

Springer Publishing Company

Access to resources Recommend Favorite

Gastroprotection in patients prescribed non-selective NSAIDs, and the risk of related hospitalization

By Koncz T. A.   Lister S. P.   Makinson G. T.  

Current Medical Research and Opinion, Vol. 24, Iss. 12, 2008-12 ,pp. : 3405-3412

Informa Healthcare

Access to resources Recommend Favorite